{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"SSE was defined as occurrence of a new symptomatic pathological fracture, use of external beam radiation to relieve bone pain, occurrence of spinal cord compression or tumor- related orthopedic surgical intervention.","groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"OG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).","id":"OG001","title":"Abiraterone Acetate or Enzalutamide"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline until occurrence of first SSE or data cut-off, whichever comes first (maximum duration: up to 141 weeks)","title":"Number of Symptomatic Skeletal Events (SSE)","type":"SECONDARY","unitOfMeasure":"events"}